Despite advances in neurosurgery, chemotherapy and radiotherapy, glioblastoma remains
one of the most treatment-resistant CNS malignancies, and the tumour inevitably recurs. The …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …

Increasing attention has been paid to the diseases of central nervous system (CNS). The
penetration efficiency of most CNS drugs into the brain parenchyma is rather limited due to …

Background Angiogenesis is a key and early step in tumorigenesis, and is known as a
hallmark of solid tumors and a key promoter of tumor recurrence. Unlike normal tissue …

Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of
different tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by …

The physiology of the vasculature in the central nervous system (CNS), which includes the
blood–brain barrier (BBB) and other factors, complicates the delivery of most drugs to the …

For glioblastoma, the tumor microenvironment (TME) is pivotal to support tumor progression
and therapeutic resistance. TME consists of several types of stromal, endothelial and …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

The existence of blood–brain barrier (BBB) hampers the effective treatment of central
nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of …